Alexandra Langlois
Professeure, Faculté de médecine et des sciences de la santé
FMSS Département de pédiatrie
Présentation
Diplômes
- (2018-2019). Food allergy fellowship. Allergologie. Université de Montréal. Montreal, Quebec, Canada.
- (2016-2018). Allergy and clinical immunology residency. Allergy and clinical immunology. Université McGill. Montreal, Quebec, Canada.
- (2013-2016). Pediatrics residency. Department of Pediatrics. Université de Sherbrooke. Sherbrooke, Quebec, Canada.
Expériences académiques
- Associate Professor. (2019-). Université de Sherbrooke. Sherbrooke, Quebec, Canada.
Financement
- Bourse. Patient- Important Outcomes in Early Introduction of Cow's Milk Formula for the Prevention of IgE- Mediated Cow’s Milk Allergy in Infants : a scoping review. Université de Sherbrooke (Sherbrooke, Canada). 10 350 $. (2025).
-
Subvention.
A 15 months, double-Blind, randomized controlled trial comparing 18 weeks of two doses of Omalizumab to placebo to accelerate a symptom-driven Oral immunotherapy schedule in subjects aged 6 to 25 years with Multiple food allergies (BOOM).
Canadian Institutes of Health Research
(Ottawa, Canada).
277 058 $.
(2019-2022).
Numéro de subvention : 201903PJT. Voir plus
Publications
Articles
- Philippe Bégin, Jeannie Callum, Erin Jamula, Richard Cook, Nancy M. Heddle, Alan Tinmouth, Michelle P. Zeller, Guillaume Beaudoin-Bussières, Luiz Amorim, Renée Bazin, Kent Cadogan Loftsgard, Richard Carl, Michaël Chassé, Melissa M. Cushing, Nick Daneman, Dana V. Devine, Jeannot Dumaresq, Dean A. Fergusson, Caroline Gabe, ... Susan Nahirniak. (2021). Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine. DOI
- Alexandra Langlois, Marie-Hélène Lavergne, Hélène Leroux, Kerstin Killer, Pauline Azzano, Louis Paradis, Kathryn Samaan, Jonathan Lacombe-Barrios, Thomas Eiwegger, Julia Upton, Gordon Sussman, Thomas Poder, Benoît Mâsse, Anne Des Roches, Philippe Bégin. (2020). Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy. Allergy, Asthma & Clinical Immunology. DOI